Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesInfectious Disease

PUBLISHER: Visiongain | PRODUCT CODE: 1457158

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 1457158

Meningococcal Vaccines Market Report 2024-2034

PUBLISHED:
PAGES: 239 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User) - 1 Year License
USD 5959.50
PDF (Team License - Up to 6 Users) - 1 Year License
USD 7055.50
PDF (Site License)
USD 8288.50
PDF (Enterprise License - Includes Free Datasets)
USD 10473.65

Add to Cart

Description

Table of Contents

List of Tables

The global Meningococcal Vaccines market is estimated at US$3,160.9 million in 2024 and is projected to grow at a CAGR of 2.5% during the forecast period 2024-2034.

The Meningococcal Vaccines Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Difficulties in R&D

Introduction of vaccine requires immense amount of research and development. Key factors that impact R&D include lack of infrastructure, limited funding opportunities, barriers to obtaining raw material, operational insufficiencies. Furthermore, R&D costs can be manageable for large dominant players while small players face various. challenges. Also, regulatory processes are complex and require lot of documentation and follow-up that further adds to time consuming process for vaccine research. Hence, there is a need to streamline R&D process for enhancing research.

What Questions Should You Ask before Buying a Market Research Report?

How is the Meningococcal Vaccines market evolving?

What is driving and restraining the Meningococcal Vaccines market?

How will each Meningococcal Vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Meningococcal Vaccines submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Meningococcal Vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Meningococcal Vaccines projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Meningococcal

Vaccines projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Meningococcal Vaccines market?

Where is the Meningococcal Vaccines market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Meningococcal Vaccines market today, and over the next 10 years:

Our 239-page report provides 105 tables, 161 charts and graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Meningococcal Vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Meningococcal Vaccines prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Type

Polysaccharide Vaccines

Conjugate Vaccines

Combination Vaccines

Men B Vaccines

Serogroups

A, B, C, Y, W-135 Vaccines

Serogroup B Vaccines

Brands

Menactra

Menveo

Nimenrix

Bexsero

Trumenba

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Meningococcal Vaccines Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

BIO-MED

GSK plc

Hualan Biological Bacterin Co., Ltd.

Incepta Pharmaceuticals Ltd.

JN International

Pfizer Inc.

Sanofi

Serum Institute of India Pvt. Ltd.

Walvax Biotechnology Co., Ltd.

Overall world revenue for Meningococcal Vaccines Market, 2024 to 2034 in terms of value the market will surpass US$3,100.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Meningococcal Vaccines Market, 2024 to 2034 report help you?

In summary, our 230+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Meningococcal Vaccines Market, 2024 to 2034 Market, with forecasts for type, serogroups, brands, and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Meningococcal Vaccines Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, U.K., Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 9 of the major companies involved in the Meningococcal Vaccines Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Meningococcal Vaccines Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Show more
Product Code: PHA1319

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Meningococcal Vaccines Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
    • 3.2.2 Market Restraining Factors
    • 3.2.3 Market Opportunities
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Supplier Power
    • 3.4.2 Buyer Power
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat of Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Meningococcal Vaccines Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Meningococcal Vaccines Market Size Estimation and Forecast by Type
  • 4.4 Polysaccharide vaccines
    • 4.4.1 Polysaccharide Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
    • 4.4.2 Polysaccharide vaccines Market Share by Region, 2024-2034 (%)
  • 4.5 Conjugate vaccines
    • 4.5.1 Conjugate Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
    • 4.5.2 Conjugate vaccines Market Share by Region, 2024-2034 (%)
  • 4.6 Combination vaccines
    • 4.6.1 Combination Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
    • 4.6.2 Combination Vaccines Market Share by Region, 2024-2034 (%)
  • 4.7 Men B vaccines
    • 4.7.1 Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
    • 4.7.2 Men B vaccines Market Share by Region, 2024-2034 (%)

5 Meningococcal Vaccines Market Analysis by Serogroups

  • 5.1 Key Findings
  • 5.2 Serogroups Segment: Market Attractiveness Index
  • 5.3 Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
  • 5.4 Meningococcal Vaccines Market Share by Serogroups, 2024 & 2034
  • 5.5 A, B, C, Y, W-135 vaccines
    • 5.5.1 A, B, C, Y, W-135 Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
    • 5.5.2 A, B, C, Y, W-135 vaccines Market Share by Region, 2024-2034 (%)
  • 5.6 Serogroup B vaccines
    • 5.6.1 Serogroup Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
    • 5.6.2 Serogroup Men B Vaccines Market Share by Region, 2024-2034 (%)

6 Meningococcal Vaccines Market Analysis by Brand

  • 6.1 Key Findings
  • 6.2 Menactra
    • 6.2.1 Menactra Market Forecast, 2024-2034 (US$ Mn)
  • 6.3 Menveo
    • 6.3.1 Menveo Market Forecast, 2024-2034 (US$ Mn)
  • 6.4 Nimenrix
    • 6.4.1 Nimenrix Market Forecast, 2024-2034 (US$ Mn)
  • 6.5 Bexsero
    • 6.5.1 Bexsero Market Forecast, 2024-2034 (US$ Mn)
  • 6.6 Trumenba
    • 6.6.1 Trumenba Market Forecast, 2024-2034 (US$ Mn)

7 Meningococcal Vaccines Market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
  • 7.4 Meningococcal Vaccines Market Share by Distribution Channel, 2024, 2029, 2034
  • 7.5 Hospital Pharmacies
    • 7.5.1 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
    • 7.5.2 Hospital Pharmacies Market Share by Region, 2024-2034 (%)
  • 7.6 Retail Pharmacies
    • 7.6.1 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
    • 7.6.2 Retail Pharmacies Market Share by Region, 2024-2034 (%)
  • 7.7 Online Pharmacies
    • 7.7.1 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
    • 7.7.2 Online Pharmacies Market Share by Region, 2024-2034 (%)

8 Meningococcal Vaccines Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Meningococcal Vaccines Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Meningococcal Vaccines Market Attractiveness Index
  • 9.3 North America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
  • 9.4 North America Meningococcal Vaccines Market Size Estimation and Forecast by Country
  • 9.5 North America Meningococcal Vaccines Market Size Estimation and Forecast by Type
  • 9.6 North America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
  • 9.7 North America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
  • 9.8 U.S.
    • 9.8.1 U.S. Meningococcal Vaccines Market by Type
  • 9.9 Canada
    • 9.9.1 Canada Meningococcal Vaccines Market by Type

10 Europe Meningococcal Vaccines Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Meningococcal Vaccines Market Attractiveness Index
  • 10.3 Europe Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
  • 10.4 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Country
  • 10.5 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Type
  • 10.6 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
  • 10.7 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
  • 10.8 Germany
    • 10.8.1 Germany Meningococcal Vaccines Market by Type
  • 10.9 U.K.
    • 10.9.1 U.K. Meningococcal Vaccines Market by Type
  • 10.10 France
    • 10.10.1 France Meningococcal Vaccines Market by Type
  • 10.11 Italy
    • 10.11.1 Italy Meningococcal Vaccines Market by Type
  • 10.12 Spain
    • 10.12.1 Spain Meningococcal Vaccines Market by Type
  • 10.13 Rest of Europe
    • 10.13.1 Rest of Europe Meningococcal Vaccines Market by Type

11 Asia Pacific Meningococcal Vaccines Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
  • 11.3 Asia Pacific Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
  • 11.4 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Type
  • 11.6 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
  • 11.7 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
  • 11.8 Japan
  • 11.9 China
    • 11.9.1 China Meningococcal Vaccines Market by Type
  • 11.10 India
    • 11.10.1 India Meningococcal Vaccines Market by Type
  • 11.11 South Korea
    • 11.11.1 South Korea Meningococcal Vaccines Market by Type
  • 11.12 Australia
    • 11.12.1 Australia Meningococcal Vaccines Market by Type
  • 11.13 Rest of APAC
    • 11.13.1 Rest of APAC Meningococcal Vaccines Market by Type

12 Latin America Meningococcal Vaccines Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Meningococcal Vaccines Market Attractiveness Index
  • 12.3 Latin America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
  • 12.4 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Country
  • 12.5 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Type
  • 12.6 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
  • 12.7 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
  • 12.8 Brazil
    • 12.8.1 Brazil Meningococcal Vaccines Market by Type
  • 12.9 Mexico
  • 12.10 Rest of Latin America
    • 12.10.1 Rest of LATAM Meningococcal Vaccines Market by Type

13 MEA Meningococcal Vaccines Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Meningococcal Vaccines Market Attractiveness Index
  • 13.3 MEA Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
  • 13.4 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Country
  • 13.5 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Type
  • 13.6 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
  • 13.7 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
  • 13.8 South Africa
    • 13.8.1 South Africa Meningococcal Vaccines Market by Type
  • 13.9 GCC
    • 13.9.1 GCC Meningococcal Vaccines Market by Type
  • 13.10 Rest of MEA
    • 13.10.1 Rest of MEA Meningococcal Vaccines Market by Type

14 Competitive Landscape

  • 14.1 Company Market Share Analysis
  • 14.2 Key Business Strategy Analysis

15 Company Profiles

  • 15.1 GSK plc
    • 15.1.1 Company Snapshot
    • 15.1.2 Company Overview
    • 15.1.3 Financial Analysis
    • 15.1.4 Product Benchmarking
    • 15.1.5 Pipeline Analysis
    • 15.1.6 Strategic Outlook
  • 15.2 BIO-MED
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Product Benchmarking
  • 15.3 Hualan Biological Bacterin Co., Ltd.
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Product Benchmarking
  • 15.4 Incepta Pharmaceuticals Ltd.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Product Benchmarking
  • 15.5 JN International
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Product Benchmarking
  • 15.6 Pfizer Inc.
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 Sanofi
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
    • 15.7.4 Product Benchmarking
    • 15.7.5 Pipeline Analysis
    • 15.7.6 Strategic Outlook
  • 15.8 Serum Institute of India Pvt. Ltd
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Product Benchmarking
    • 15.8.4 Strategic Outlook
  • 15.9 Walvax Biotechnology Co., Ltd.
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Pipeline Analysis

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
Show more
Product Code: PHA1319

List of Tables

  • Table 1 Meningococcal Vaccines Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 2 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (V-shaped Recovery)
  • Table 3 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (U-shaped Recovery)
  • Table 4 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (W-shaped Recovery)
  • Table 5 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (L-shaped Recovery)
  • Table 6 Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 7 Polysaccharide Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 8 Conjugate Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 9 Combination Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 10 Men B Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 11 Meningococcal Vaccines Market by Serogroups, By Type 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 12 A, B, C, Y, W-135 Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 13 Men B Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 14 Menactra Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 15 Menveo Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 16 Nimenrix Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 17 Bexsero Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 18 Trumenba Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 19 Meningococcal Vaccines Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 20 Hospital Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 21 Retail Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 22 Online Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 23 Meningococcal Vaccines Market, By Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 24 North America Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 25 North America Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 26 North America Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 27 North America Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 28 U.S. Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 29 U.S. Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 30 Canada Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 31 Canada Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 32 Europe Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 33 Europe Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 34 Europe Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 35 Europe Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 36 Germany Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 37 Germany Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 38 U.K. Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 39 UK Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 40 France Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 41 France Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 42 Italy Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 43 Italy Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 44 Spain Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 45 Spain Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 46 Rest of Europe Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 47 Rest of Europe Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 48 Asia Pacific Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 49 Asia Pacific Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 50 Asia Pacific Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 51 Asia Pacific Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 52 China Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 53 China Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 54 India Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 55 India Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 56 South Korea Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 57 South Korea Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 58 Australia Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 59 Australia Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 60 Rest of Asia Pacific Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 61 Rest of Asia Pacific Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 62 Latin America Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 63 Latin America Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 64 Latin America Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 65 Latin America Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 66 Brazil Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 67 Brazil Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 68 Rest of LATAM Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 69 Rest of LATAM Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 70 MEA Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 71 MEA Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 72 MEA Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 73 MEA Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 74 South Africa Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 75 South Africa Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 76 GCC Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 77 GCC Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 78 Rest of MEA Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 79 Rest of MEA Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 80 Key Business Strategies Adopted by Key Players in Meningococcal Vaccines Market Details
  • Table 81 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 GSK plc: Product Benchmarking
  • Table 83 GSK plc: Product Pipeline
  • Table 84 GSK plc: Company Recent Developments
  • Table 85 BIO-MED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 BIO-MED: Product Benchmarking
  • Table 87 Hualan Biological Bacterin Co., Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Hualan Biological Bacterin Co., Ltd: Product Benchmarking
  • Table 89 Incepta Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Incepta Pharmaceuticals Ltd.: Product Benchmarking
  • Table 91 JN International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 JN International: Product Benchmarking
  • Table 93 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Pfizer Inc.: Product Benchmarking
  • Table 95 Pfizer Inc.: Company Recent Developments
  • Table 96 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Sanofi: Product Benchmarking
  • Table 98 Sanofi: Product Pipeline
  • Table 99 Sanofi: Company Recent Developments
  • Table 100 Serum Institute of India Pvt. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Serum Institute of India Pvt. Ltd: Product Benchmarking
  • Table 102 Serum Institute of India Pvt. Ltd: Company Recent Developments
  • Table 103 Walvax Biotechnology Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Walvax Biotechnology Co., Ltd.: Product Benchmarking
  • Table 105 Walvax Biotechnology Co., Ltd.: Product Pipeline

List of Figures

  • Figure 1 Meningococcal Vaccines Market Segmentation
  • Figure 2 Meningococcal Vaccines Market Forecast by Region: Market Attractiveness Index
  • Figure 3 Meningococcal Vaccines Market by Type: Market Attractiveness Index
  • Figure 4 Meningococcal Vaccines Market by Serogroups: Market Attractiveness Index
  • Figure 5 Meningococcal Vaccines Market by Distribution Channel: Market Attractiveness Index
  • Figure 6 Meningococcal Vaccines Market: Market Dynamics
  • Figure 7 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "V" Shaped Recovery
  • Figure 8 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "U" Shaped Recovery
  • Figure 9 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "W" Shaped Recovery
  • Figure 10 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "L" Shaped Recovery
  • Figure 11 Meningococcal Vaccines Market: Porter's Five Forces Analysis
  • Figure 12 Meningococcal Vaccines Market: PEST Analysis
  • Figure 13 Meningococcal Vaccines Market Forecast by Type 2023 (Revenue, CAGR%)
  • Figure 14 Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 15 Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 16 Polysaccharide Vaccines Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 17 Polysaccharide vaccines Market Share Forecast by Region, 2024-2034 (%)
  • Figure 18 Conjugate Vaccines Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 19 Conjugate vaccines Market Share Forecast by Region, 2024-2034 (%)
  • Figure 20 Combination Vaccines Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 21 Combination Vaccines Market Share Forecast by Region, 2024-2034 (%)
  • Figure 22 Men B Vaccines Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 23 Men B vaccines Market Share Forecast by Region, 2024-2034 (%)
  • Figure 24 Meningococcal Vaccines Market Forecast by Serogroups 2023 (Revenue, CAGR%)
  • Figure 25 Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
  • Figure 26 Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
  • Figure 27 A, B, C, Y, W-135 Vaccines Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 28 A, B, C, Y, W-135 vaccines Market Share Forecast by Region, 2024-2034 (%)
  • Figure 29 Serogroup Men B Vaccines Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 30 Serogroup Men B Vaccines Market Share Forecast by Region, 2024-2034 (%)
  • Figure 31 Menactra Market Forecast, 2024-2034 (US$ million)
  • Figure 32 Menveo Market Forecast, 2024-2034 (US$ million)
  • Figure 33 Nimenrix Market Forecast, 2024-2034 (US$ million)
  • Figure 34 Bexsero Market Forecast, 2024-2034 (US$ million)
  • Figure 35 Trumenba Market Forecast, 2024-2034 (US$ million)
  • Figure 36 Meningococcal Vaccines Market Forecast by Distribution Channel 2023 (Revenue, CAGR%)
  • Figure 37 Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 38 Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 39 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 40 Hospital Pharmacies Market Share Forecast by Region, 2024-2034 (%)
  • Figure 41 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 42 Retail Pharmacies Market Share Forecast by Region, 2024-2034 (%)
  • Figure 43 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
  • Figure 44 Online Pharmacies Market Share Forecast by Region, 2024-2034 (%)
  • Figure 45 Meningococcal Vaccines Market Forecast by Region 2024, 2034 (Revenue)
  • Figure 46 Meningococcal Vaccines Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 47 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Figure 48 North America Meningococcal Vaccines Market Attractiveness Index
  • Figure 49 North America Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
  • Figure 50 North America Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 51 North America Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034(%)
  • Figure 52 North America Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 53 North America Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 54 North America Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
  • Figure 55 North America Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
  • Figure 56 North America Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 57 North America Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 58 U.S. Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 59 U.S. Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 60 U.S. Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 61 Canada Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 62 Canada Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 63 Canada Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 64 Europe Meningococcal Vaccines Market Attractiveness Index
  • Figure 65 Europe Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
  • Figure 66 Europe Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 67 Europe Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
  • Figure 68 Europe Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 69 Europe Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 70 Europe Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
  • Figure 71 Europe Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
  • Figure 72 Europe Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 73 Europe Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 74 Germany Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 75 Germany Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 76 Germany Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 77 UK Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 78 U.K. Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 79 U.K. Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 80 France Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 81 France Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 82 France Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 83 Italy Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 84 Italy Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 85 Italy Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 86 Spain Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 87 Spain Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 88 Spain Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 89 Rest of Europe Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 90 Rest of Europe Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Rest of Europe Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 92 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
  • Figure 93 Asia Pacific Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
  • Figure 94 Asia Pacific Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 95 Asia Pacific Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
  • Figure 96 Asia Pacific Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 97 Asia Pacific Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 98 Asia Pacific Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
  • Figure 99 Asia Pacific Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
  • Figure 100 Asia Pacific Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 101 Asia Pacific Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 102 China Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 103 China Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 104 China Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 105 India Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 106 India Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 107 India Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 108 South Korea Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 109 South Korea Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 110 South Korea Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 111 Australia Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 112 Australia Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 113 Australia Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 114 Rest of Asia Pacific Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 115 Rest of APAC Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Rest of APAC Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 117 Latin America Meningococcal Vaccines Market Attractiveness Index
  • Figure 118 Latin America Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
  • Figure 119 Latin America Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 120 Latin America Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
  • Figure 121 Latin America Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 122 Latin America Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 123 Latin America Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
  • Figure 124 Latin America Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
  • Figure 125 Latin America Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 126 Latin America Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 127 Brazil Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 128 Brazil Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 129 Brazil Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 130 Rest of LATAM Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Rest of LATAM Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Rest of LATAM Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 133 MEA Meningococcal Vaccines Market Attractiveness Index
  • Figure 134 MEA Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
  • Figure 135 MEA Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 136 MEA Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
  • Figure 137 MEA Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 138 MEA Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 139 MEA Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
  • Figure 140 MEA Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
  • Figure 141 MEA Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 142 MEA Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 143 South Africa Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 144 South Africa Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 145 South Africa Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 146 GCC Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 GCC Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 148 GCC Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 149 Rest of MEA Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 150 Rest of MEA Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 151 Rest of MEA Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 152 Meningococcal Vaccines Market: Company Market Share Analysis, 2022
  • Figure 153 GSK plc: Net Revenue, 2018-2022 (US$ Million, AGR %)
  • Figure 154 GSK plc: Regional Market Shares, 2022
  • Figure 155 GSK plc: R&D, 2018-2022 (US$ Million, AGR %)
  • Figure 156 Pfizer Inc.: Net Revenue, 2018-2022 (US$ Million, AGR %)
  • Figure 157 Pfizer Inc.: Regional Market Shares, 2022
  • Figure 158 Pfizer Inc.: R&D, 2018-2022 (US$ Million, AGR %)
  • Figure 159 Sanofi: Net Revenue, 2018-2022 (US$ Million, AGR %)
  • Figure 160 Sanofi: Regional Market Shares, 2022
  • Figure 161 Sanofi: R&D, 2018-2022 (US$ Million, AGR %)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!